Status:
COMPLETED
Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive Chemotherapy
Lead Sponsor:
M.D. Anderson Cancer Center
Conditions:
Sarcoma
Eligibility:
All Genders
13+ years
Phase:
PHASE3
Brief Summary
Intensive chemotherapy is often associated with low platelet counts often requiring platelet transfusions to maintain platelet counts. In previous clinical studies administration of rhTPO has been dem...
Detailed Description
To evaluate the effectiveness of intravenous rhTPO vs. placebo as primary prophylaxis in reducing the cumulative proportion of patients requiring platelet transfusion for severe chemotherapy-induced t...
Eligibility Criteria
Inclusion
- Confirmed new diagnosis of moderate or high-grade sarcoma (except leiomyosarcoma of gastrointestinal origin)
- Must have high risk disease by American Joint Committee on Cancer (AJCC) Staging System Stage IIC, III, or IV
- Must have recovered from surgery for a minimum of 2 weeks
- Must be scheduled for a minimum of 4 cycles of AI therapy
- Must be 13 years or older
- Must have ECOG performance status of 0, 1, or 2.
- Must have life expectancy of at least 12 weeks.
- Left ventricular ejection fraction must be more than 50%.
- Laboratory data within normal limits.
Exclusion
- Prior front-line standard or experimental therapy for sarcoma
- History of bone marrow and or peripheral blood progenitor cell transplantation
- Prior pelvic radiation or radiation therapy to more than 25% of bone marrow reserves
- Prior treatment with megakaryocyte growth and differentiation factor
- Prior treatment with rhTPO
- History of platelet disorder
- History of myocardial infarction, stroke, pulmonary embolism, or deep vein thrombosis within the past 12 months
- Pregnant or lactating women
- Use of anticoagulants such as coumadin, heparin, etc.
- Known HIV or hepatitis
Key Trial Info
Start Date :
June 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2004
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00283582
Start Date
June 1 2001
End Date
November 1 2004
Last Update
October 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT MD Anderson Cancer Center
Houston, Texas, United States, 77030